FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
|Articles|January 31, 2022
Genome Mapping Reveals Key Structural Variants Impacting COVID-19 Disease Severity
Author(s)Nina Cosdon
The first study to use optical genome mapping to assess severely ill COVID-19 patients identified 7 key structural variants.
Advertisement
One of the greatest mysteries of COVID-19 infection is the varying nature of disease severity; COVID-19 causes mortality in some yet no symptoms in others.
One study, published in
“Millions of people get infected, and fortunately only a very small percentage become symptomatic, and a very small percentage of the symptomatic individuals require oxygen and a small percentage of those individuals are hospitalized and die,” said Dr. Ravindra Kolhe, a corresponding author of the study and the director of the Georgia Esoteric and Molecular Laboratory at the Medical College of Georgia at Augusta University. “But even a small percentage amounts to millions of people and that is too many.”
The first-of-its-kind study used optical genome mapping to identify structural variations that could be predisposition factors associated with severe COVID-19 disease.
The investigators included 52 severely ill COVID-19 patients to identify rare structural variants. Their 3-dimensional assessment of the genome revealed rare structural variants in 9 of the sickest patients, affecting a total of 31 genes that mediated the pathways between host and virus.
The 9 sickest patients shared common comorbidities, while 32 required mechanical ventilation and 13 of the 52 died while in the intensive care unit.
The investigators identified 7 structural variants involving genes implicated in innate immunity and inflammatory response, and viral replication and spread, both key host-viral interaction pathways. The results may explain the clinical variability in response to COVID-19 among different individuals.
The investigators noted that the large structural variants they identified were not caused by COVID-19, but rather the virus used the variants to its advantage. The identified structural variants may not increase susceptibility to conditions other than SARS-CoV-2.
This research points to a need for an assay to test for genetic variants that, once identified, would allow for early vaccination and other protective measures among individuals more susceptible to severe COVID-19 infection and disease.
Advertisement
Related to this article
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.
The FDA has approved formulations for the 2026-2027 vaccines including Pfizer-BioNTech's Comirnaty XFG, Novavax's commercial partners Sanofi and Takeda have secured approvals for its Nuvaxovid, and Moderna's Spikevax and mNEXSPIKE vaccines, all with protections against the currently circulating variant.
The FDA has approved Pfizer-BioNTech's 2026-2027 Comirnaty XFG formula, an updated COVID-19 vaccine targeting the XFG variant, for adults 65 and older and for individuals ages five through 64 with at least one high-risk underlying condition.
Venky Soundararajan, PhD, co-founder and chief scientific officer of nference, explains what the semaglutide-COVID-19/influenza data can and can't tell clinicians about mechanism, bias, and the evidence bar before it should shape prescribing.
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
Advertisement
Advertisement